Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam-Reference-Cited by-同舟云学术

Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam

Published:2006-09 Issue:3 Volume:68 Page:615-620
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

van der Cruijsen-Koeter Ingrid W.,Roobol Monique J.,Wildhagen Mark F.,van der Kwast T.H.,Kirkels W.J.,Schröder Fritz H.

Publisher

Elsevier BV

Subject

Urology

Reference17 articles.

1. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Study of Screening for Prostate Cancer (ERSPC) trial;de Koning;Int J Cancer,2002

2. Prospective evaluation plan for randomised trials of prostate cancer screening;Auvinen;J Med Screening,1996

3. Implications of stage specific survival rates in assessing recent declines in prostate cancer mortality rates;Tarone;Epidemiology,2000

4. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial;Labrie;Prostate,1999

5. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria;Bartsch;Urology,2001

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI;JAMA;2024-05-07

2. A Pragmatic Approach to Prostate Cancer Screening;JAMA;2024-05-07

3. Computational Modeling With Phantom-Tissue Validation of Gold-Nanorod-Enhanced Laser Ablation of Prostate Cancer;ASME Journal of Heat and Mass Transfer;2023-10-23

4. Development of a computational simulation tool to design a protocol for treating prostate tumours using transurethral laser photothermal therapy;International Journal of Hyperthermia;2014-09

5. Defining the threshold for significant versus insignificant prostate cancer;Nature Reviews Urology;2013-05-28